Covid-19 Vaccination Mandate
Cody C made this Official Information request to Airways Corporation of New Zealand Limited
The request was successful.
From: Cody C
Dear Airways Corporation of New Zealand Limited,
Please advise total number of staff that are not vaccinated and the total number of staff.
Please also provide your Covid-19 vaccination policy.
Yours faithfully,
Cody C
From: Cody C
Dear Airways Corporation of New Zealand Limited,
Please acknowledge request. OIA applies.
Yours faithfully,
Cody C
From: Christian, Marielle
Airways Corporation of New Zealand Limited
Hi Cody
This is just a quick email to acknowledge receipt of your official
information request dated 25 January 2022 for:
o Total number of staff that are not vaccinated
o Total number of staff
o Airways Covid-19 vaccination policy
I will endeavour to respond to your request as soon as reasonably
practicable and in any event no later than 23 February 2022, being 20
working days after the day your request was received.
Ngā mihi
Marielle
Marielle Christian
Senior Legal Counsel
[1]http://www.airways.co.nz/assets/images/E...
Level 2, 6 Leonard Isitt Drive, Auckland Airport, Auckland 2022
PO Box 53093, Auckland, 2150
ddi. +64 9 257 7812 ext 9712
m. +64 27 251 5838
e. [2][email address]
w. [3]www.airways.co.nz
[4]http://www.airways.co.nz/assets/images/E...
[6]http://www.airways.co.nz/assets/images/E...
[7]http://www.airways.co.nz/assets/images/E...
Your communications are important to us and we take appropriate
measures to access, store and scan for information assurance.
This electronic message together with any attachments is confidential. If
you receive it in error: (i) you must not use, disclose, copy or retain
it; (ii) please contact the sender immediately by reply email and then
delete the emails. Views expressed in this email may not be those of the
Airways Corporation of New Zealand Limited.
References
Visible links
1. http://www.airways.co.nz/
2. mailto:[email address]
3. http://www.airways.co.nz/
4. https://twitter.com/AirwaysNZ
5. https://www.facebook.com/AirwaysNZ
6. https://www.linkedin.com/company/48243/
7. https://www.youtube.com/airwaysnz
From: Christian, Marielle
Airways Corporation of New Zealand Limited
Hi Cody
Please see attached letter of today’s date.
Kind regards
Marielle
Marielle Christian
Senior Legal Counsel
[1]http://www.airways.co.nz/assets/images/E...
Level 2, 6 Leonard Isitt Drive, Auckland Airport, Auckland 2022
PO Box 53093, Auckland, 2150
ddi. +64 9 257 7812 ext 9712
m. +64 27 251 5838
e. [2][email address]
w. [3]www.airways.co.nz
[4]http://www.airways.co.nz/assets/images/E...
[6]http://www.airways.co.nz/assets/images/E...
[7]http://www.airways.co.nz/assets/images/E...
Your communications are important to us and we take appropriate
measures to access, store and scan for information assurance.
This electronic message together with any attachments is confidential. If
you receive it in error: (i) you must not use, disclose, copy or retain
it; (ii) please contact the sender immediately by reply email and then
delete the emails. Views expressed in this email may not be those of the
Airways Corporation of New Zealand Limited.
References
Visible links
1. http://www.airways.co.nz/
2. mailto:[email address]
3. http://www.airways.co.nz/
4. https://twitter.com/AirwaysNZ
5. https://www.facebook.com/AirwaysNZ
6. https://www.linkedin.com/company/48243/
7. https://www.youtube.com/airwaysnz
Things to do with this request
- Add an annotation (to help the requester or others)
- Download a zip file of all correspondence
SPENCER JONES left an annotation ()
International Journal of Vaccine Theory, Practice, and Research 4(1)
https://doi.org/10.56098/hqjnk479
From Innovation to Inquiry — COVID -19 mRNA
Vaccination and Its Global Consequences —
with Special Reference to New Zealand
Bruce Rapley, PhD
Consultant and Independent Researcher, Smart Technology, New Zealand;
Abstract
The COVID-19 pandemic involved the rapid deployment of novel biomedical technologies. Chief
among them were synthetic RNAs, introduced with limited longitudinal data, yet supported by
institutional consensus, and expedited regulatory pathways. Subsequent developments revealed
questions regarding safety, ethics, efficacy, and governance. This formal review, with specific
reference to New Zealand, examines the COVID-19 response, using synthetic RNA distributed
under Emergency Use Authorizations. A range of post-deployment signals, including immunological
anomalies (IgG4 class switching), clotting disorders, and residual DNA elements, remain
insufficiently investigated. Regulatory responses have not met the standard of precaution typically
applied to novel gene therapies. At the same time, low-cost interventions such as ivermectin were de-
prioritized, or suppressed. The temporal association between vaccine rollouts and excess non-
COVID mortality in several high-uptake nations warrants systematic, transparent analysis. To date,
no national authority has published comprehensive disaggregated mortality data by vaccination
status.
Keywords: adverse events, COVID-19 vaccination, Emergency Use Authorization, EUA, genetic engineering, IgG4 class
switching, mRNA vaccination, plasmid DNA, post-market surveillance, therapeutic suppression, ivermectin, spike protein toxicity,
regulatory oversight failure, scientific censorship, turbo cancer, vaccine-induced thrombotic thrombocytopenia, VITT
Link to this